Results 41 to 50 of about 1,005 (173)

Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin‐1 Levels

Journal of Sleep Research, EarlyView.
ABSTRACT Narcolepsy is classified as type 1 (NT1) or type 2 (NT2) mainly according to hypocretin deficiency rather than cataplexy. While CRH neuron loss in the PVN has been described in NT1, it remains unclear whether similar changes occur in narcolepsy without cataplexy.
Ling Shan, Suzan Linssen, Rolf Fronczek, Lucie Barateau, Christelle Peyron, Yves Dauvilliers   +5 more
wiley   +1 more source

Przekaźnictwo histaminergiczne w narkolepsji typu 1 – implikacje terapeutyczne

Aktualności Neurologiczne, 2018
Narkolepsja typu 1 (narkolepsja z katapleksją) jest chorobą objawiającą się nadmierną sennością dzienną, niekontrolowanym zasypianiem, epizodami katapleksji (nagłej utraty napięcia mięśniowego), halucynacjami hipnagogicznymi i hipnopompicznymi oraz ...
Mariusz Siemiński
doaj   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Increased Sensitivity of Mice Lacking Extrasynaptic δ-Containing GABAA Receptors to Histamine Receptor 3 Antagonists

Frontiers in Pharmacology, 2020
Histamine/gamma-aminobutyric acid (GABA) neurons of posterior hypothalamus send wide projections to many brain areas and participate in stabilizing the wake state.
Shamsiiat Abdurakhmanova, Milo Grotell, Jenna Kauhanen, Anni-Maija Linden, Esa R. Korpi, Pertti Panula   +5 more
doaj   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, Volume 12, Issue 2, Page 100-112, June 2026.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model [PDF]

, 2020
Purpose: Histamine H3 receptor ligands may have antidepressant and anxiolytic effects. They can also compensate for metabolic disorders, which affect glucose or triglyceride levels.
Mika, Kamil, Sapa, Jacek, Kotańska, Magdalena, Wheeler, Lee, Kieć-Kononowicz, Katarzyna, Pytka, Karolina, Sałaciak, Kinga   +6 more
core   +1 more source

Attention‐deficit hyperactivity disorder in children and young persons during the COVID‐19 pandemic. A temporal trends analysis of electronic heath records in Greater Manchester, England

JCPP Advances, Volume 6, Issue 2, June 2026.
Abstract Background The incidence of attention‐deficit hyperactivity disorder (ADHD) in children and young people has increased in recent years. Disease frequency varies according to sociodemographic characteristics. There are seasonal patterns in ADHD diagnosis and prescribing with rates falling during school holidays.
Louise Hussey, Evangelos Kontopantelis, Pearl L. H. Mok, Darren M. Ashcroft, Shruti Garg, Carolyn A. Chew‐Graham, Karina Lovell, Roger T. Webb   +7 more
wiley   +1 more source

Selective H3 Antagonist (ABT-239) Differentially Modifies Cognitive Function Under the Impact of Restraint Stress

Frontiers in Systems Neuroscience, 2021
Background: A considerable number of competitive antagonists/inverse agonists of histamine H3 receptor (H3R) have progressed to clinical assessment, with pitolisant approved for the treatment of narcolepsy.
Emil Trofimiuk, Przemysław Wielgat, Halina Car   +2 more
doaj   +1 more source

Narcolepsy in the light of modern diagnostic, clinical and therapeutic concepts

Journal of Education, Health and Sport, 2018
Narcolepsy is a chronic neurological disease classified as hypersomnia of central origin. Core symptoms of the disease (hypersomnia and cataplexy) are particularly burdensome for patients. The etiology of the disease is not fully understood.
Adrian Kowalski, Iwona Kowalska, Magdalena Kowalska, Wiktor Dróżdż, Alicja Nowaczyk   +4 more
doaj   +3 more sources

Multiple Targeting Approaches on Histamine H3 Receptor Antagonists

Frontiers in Neuroscience, 2016
With the very recent market approval of pitolisant (Wakix®), the interest in clinical applications of novel multifunctional histamine H3 receptor antagonists has clearly increased. Since histamine H3 receptor antagonists in clinical development have been
Mohammad eKhanfar, Anna eAffini, Kiril eLutsenko, Katarina eNikolic, Stefania eButini, Holger eStark   +5 more
doaj   +1 more source